{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:09:26Z","timestamp":1793653766441,"version":"4.5.1"},"reference-count":60,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2022,2,16]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review aimed to highlight the current evidence and recommendations of antiplatelet therapy for stroke prevention.<\/jats:p>\n                  <jats:p>We conducted advanced literature search for antiplatelet therapy. Landmark studies and randomised controlled trials evaluating antiplatelet therapy for secondary stroke prevention are reviewed. Results from Cochrane systematic review, pooled data analysis and meta-analysis are discussed.<\/jats:p>\n                  <jats:p>Single-antiplatelet therapy (SAPT) with aspirin, aspirin\/extended-release dipyridamole or clopidogrel reduces the risk of recurrent ischaemic stroke in patients with non-cardioembolic ischaemic stroke or transient ischaemic attack (TIA). Dual-antiplatelet therapy (DAPT) with aspirin and clopidogrel or ticagrelor for 21\u201330\u2009days is more effective than SAPT in patients with minor acute noncardioembolic ischaemic stroke or high-risk TIA. Prolonged use of DAPT is associated with higher risk of haemorrhage without reduction in stroke recurrence than SAPT. Compared with placebo, aspirin reduces the relative risk of recurrent stroke by approximately 22%. Aspirin\/dipyridamole and cilostazol are superior to aspirin but associated with significant side effects. Cilostazol or ticagrelor might be more effective than aspirin or clopidogrel in patients with intracranial stenosis.<\/jats:p>\n                  <jats:p>SAPT is indicated for secondary stroke prevention in patients with non-cardioembolic ischaemic stroke or TIA. DAPT with aspirin and clopidogrel or ticagrelor for 21\u201330\u2009days followed by SAPT is recommended for patients with minor acute noncardioembolic stroke or high-risk TIA. Selection of appropriate antiplatelet therapy should also be based on compliance, drug tolerance or resistance.<\/jats:p>","DOI":"10.1136\/svn-2021-001166","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T12:50:48Z","timestamp":1649335848000},"page":"406-414","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":56,"title":["Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines"],"prefix":"10.1136","volume":"7","author":[{"given":"Jay","family":"Shah","sequence":"first","affiliation":[{"name":"Neurology, University of California, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-1778","authenticated-orcid":false,"given":"Shimeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Neurology, University of California, Irvine, California, USA"},{"name":"Neurology, Tiantan Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1664-3580","authenticated-orcid":false,"given":"Wengui","family":"Yu","sequence":"additional","affiliation":[{"name":"Neurology, University of California, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"2025081709372408000_7.5.406.1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"2025081709372408000_7.5.406.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.06.039"},{"key":"2025081709372408000_7.5.406.3","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.008422"},{"key":"2025081709372408000_7.5.406.4","article-title":"Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients","author":"Sudlow","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2025081709372408000_7.5.406.5","doi-asserted-by":"crossref","unstructured":"Sandercock PAG , Counsell C , Tseng M-C , et al . Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev;349.doi:10.1002\/14651858.CD000029.pub3","DOI":"10.1002\/14651858.CD000029.pub3"},{"key":"2025081709372408000_7.5.406.6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11239-018-1786-z","article-title":"Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials","volume":"47","author":"Kheiri","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"2025081709372408000_7.5.406.7","article-title":"Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack","volume":"8","author":"Naqvi","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025081709372408000_7.5.406.8","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/CIRCULATIONAHA.121.053782","article-title":"Efficacy and safety of using dual versus monotherapy antiplatelet agents in secondary stroke prevention: systematic review and meta-analysis of randomized controlled clinical trials","volume":"143","author":"Trifan","year":"2021","journal-title":"Circulation"},{"key":"2025081709372408000_7.5.406.9","doi-asserted-by":"crossref","first-page":"e468-e479","DOI":"10.1161\/STR.0000000000000377","article-title":"Benefits and risks of dual versus single antiplatelet therapy for secondary stroke prevention: a systematic review for the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack","volume":"52","author":"Brown","year":"2021","journal-title":"Stroke"},{"key":"2025081709372408000_7.5.406.10","doi-asserted-by":"crossref","unstructured":"Kleindorfer DO , Towfighi A , Chaturvedi S , et al . 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American heart Association\/American stroke association. Stroke 2021;52.doi:10.1161\/STR.0000000000000375","DOI":"10.1161\/STR.0000000000000375"},{"key":"2025081709372408000_7.5.406.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6921.81"},{"key":"2025081709372408000_7.5.406.12","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19\u2008435 patients with acute ischaemic stroke","volume":"349","year":"1997","journal-title":"The Lancet"},{"key":"2025081709372408000_7.5.406.13","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"CAST: randomised placebo-controlled trial of early aspirin use in 20\u2008000 patients with acute ischaemic stroke","volume":"349","author":"Chen","year":"1997","journal-title":"The Lancet"},{"key":"2025081709372408000_7.5.406.14","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(83)90356-0"},{"key":"2025081709372408000_7.5.406.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91254-2"},{"key":"2025081709372408000_7.5.406.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(96)00308-5"},{"key":"2025081709372408000_7.5.406.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68734-5"},{"key":"2025081709372408000_7.5.406.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805002"},{"key":"2025081709372408000_7.5.406.19","doi-asserted-by":"publisher","DOI":"10.1053\/jscd.2000.7216"},{"key":"2025081709372408000_7.5.406.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70198-8"},{"key":"2025081709372408000_7.5.406.21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol"},{"key":"2025081709372408000_7.5.406.22","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.029454"},{"key":"2025081709372408000_7.5.406.23","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.15.1667"},{"key":"2025081709372408000_7.5.406.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"2025081709372408000_7.5.406.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603060"},{"key":"2025081709372408000_7.5.406.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30038-8"},{"key":"2025081709372408000_7.5.406.27","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000165918.80812.1e"},{"key":"2025081709372408000_7.5.406.28","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.106.476648"},{"key":"2025081709372408000_7.5.406.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16721-4"},{"key":"2025081709372408000_7.5.406.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060989"},{"key":"2025081709372408000_7.5.406.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204133"},{"key":"2025081709372408000_7.5.406.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"2025081709372408000_7.5.406.33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014791"},{"key":"2025081709372408000_7.5.406.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800410"},{"key":"2025081709372408000_7.5.406.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916870"},{"key":"2025081709372408000_7.5.406.36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamaneurol.2020.4396","article-title":"Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke","volume":"78","author":"Amarenco","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025081709372408000_7.5.406.37","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.032239"},{"key":"2025081709372408000_7.5.406.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105335"},{"key":"2025081709372408000_7.5.406.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62038-3"},{"key":"2025081709372408000_7.5.406.40","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA","volume":"385","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"key":"2025081709372408000_7.5.406.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32849-0"},{"key":"2025081709372408000_7.5.406.42","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaneurol.2021.2956","article-title":"Effects of antiplatelet therapy after stroke caused by intracerebral hemorrhage: extended follow-up of the restart randomized clinical trial","volume":"78","author":"Al-Shahi Salman","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025081709372408000_7.5.406.43","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000757"},{"key":"2025081709372408000_7.5.406.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68040-9"},{"key":"2025081709372408000_7.5.406.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2009.11.004"},{"key":"2025081709372408000_7.5.406.46","doi-asserted-by":"publisher","DOI":"10.1159\/000069490"},{"key":"2025081709372408000_7.5.406.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.10.012"},{"key":"2025081709372408000_7.5.406.48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1586\/ern.10.203","article-title":"Antiplatelet resistance in stroke","volume":"11","author":"Top\u00e7uoglu","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"2025081709372408000_7.5.406.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61525-7"},{"key":"2025081709372408000_7.5.406.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"2025081709372408000_7.5.406.51","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8662"},{"key":"2025081709372408000_7.5.406.52","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jamaneurol.2019.0072","article-title":"Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection: the cervical artery dissection in stroke study (CADISS) randomized clinical trial final results","volume":"76","author":"Markus","year":"2019","journal-title":"JAMA Neurol"},{"key":"2025081709372408000_7.5.406.53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01351.x"},{"key":"2025081709372408000_7.5.406.54","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017895"},{"key":"2025081709372408000_7.5.406.55","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024913"},{"key":"2025081709372408000_7.5.406.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043033"},{"key":"2025081709372408000_7.5.406.57","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.609370"},{"key":"2025081709372408000_7.5.406.58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369610","article-title":"Final results of Cilostazol-Aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS)","volume":"5","author":"Uchiyama","year":"2015","journal-title":"Cerebrovasc Dis Extra"},{"key":"2025081709372408000_7.5.406.59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05388-X"},{"key":"2025081709372408000_7.5.406.60","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017217"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2021-001166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:37:37Z","timestamp":1755448657000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2021-001166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,10,25]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/svn-2021-001166"],"URL":"https:\/\/doi.org\/10.1136\/svn-2021-001166","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}